Shots: The P-III A4091058 study involves assessing of Tanezumab (2.5 & 5mg, q8w) vs NSAIDS (naproxen 500 mg/celecoxib 100 mg/diclofenac extended release 75 mg, q2d) in 3,021 patients with moderate-to-severe […]readmore
Tags : Report
Shots: The P-III MMY3021 study involves assessing of daratumumab (1800mg, SC) + lenalidomide vs lenalidomide as monothx. in 214 newly diagnosed multiple myeloma patients who are MRD + after autologous […]readmore
Shots: The P-III MAPLE study involves assessing of abicipar pegol (2mg, q8w) in 123 patients with Neovascular Macular Degeneration (nAMD) for 28 wks. P-III MAPLE study results: 8.9% incidence of […]readmore
Shots: The P-III FINCH-3 study involves assessing of filgotinib (100/200 mg) + methotrexate (MTX) vs filgotinib (200mg)/MTX as monothx in 1252 patients in ratio (2:1:1:2) with moderate to severe active […]readmore
Shots: The P-III A4091059 study involves assessing of tanezumab (5mg,10mg) vs PBO vs tramadol (prolonged release) in 1,832 in the ratio 2:2:2:3 with moderate-to-severe chronic low back pain (CLBP) in […]readmore
Shots: The P-III study involves assessing of isatuximab (10mg/kg qw for 4 wks.) + pomalidomide & low dose dexamethasone vs pomalidomide + low dose dexamethasone monothx in 307 patients with […]readmore
Shots: The P-III OA study involves assessing of tanezumab (2.5mg/5mg, SC) vs PBO in 849 patients in the ratio (1:1:1) with moderate-to-severe OA pain of the knee or hip across […]readmore
Shots: The P-III EXPEDITION Study involves assessing of Solanezumab (400 mg, IV, q4w) vs PBO in 1,012 (EXPEDITION1) & 1,040 (EXPEDITION2) patients with mild or mild to moderate Alzheimer disease […]readmore